Could diabetes drugs protect kidneys after acute injury?

NCT ID NCT06528405

Recruiting now Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether SGLT2 inhibitors, drugs already used for diabetes and chronic kidney disease, can help people with acute kidney disease (AKD). AKD occurs between 7 and 90 days after a kidney injury and can lead to chronic kidney disease. The trial will give either the drug or a placebo to 264 adults with AKD, measuring changes in urine protein and kidney function. The goal is to see if these drugs can safely improve kidney outcomes and prevent long-term damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SGLT2 inhibitors (dapagliflozin or empagliflozin)
What this could lead to: If successful, this could offer a new treatment to prevent acute kidney disease from turning into chronic kidney disease, improving long-term kidney health.
What could go wrong: This is an early phase 2 trial with only 264 participants, so results may not apply to everyone. The drugs may cause side effects like dehydration or infection, and the benefit is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury Albuminuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY

Contacts and locations

Locations

National Taiwan University Hospital
RECRUITING

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.